Department of Cytogenetics
Department of Laboratory Sciences
Department of Laboratory Sciences
About the Department
The Cytogenetics laboratory at TMC is a the only NABL accredited state-of-the-art laboratory in Eastern India which provides comprehensive cytogenetic services in both haematological malignancies and solid tumors.
Cytogenetic characterization of tumors plays a pivotal role in the diagnosis, risk stratification, prognosis, therapeutic selection and monitoring of treatment in various hematological and solid malignancies. The laboratory handles more than 3000 samples annually that include peripheral blood, bone marrow and solid tumor tissue samples. The department organizes numerous CMEs and workshops and has trained people in India and abroad helping them set up cytogenetic laboratories. The team has formulated efficient cost effective strategies and algorithms to genomically characterize tumor cells that can be applied in low resource settings. Their work has resulted in numerous publications in national and international peer reviewed journals.
The department has three automated karyotyping and FISH workstations with automated scanning and Imaging Platform for automatic capture of metaphases as well as aautomated fluorescence in-situ hybridization analysis (FISH signal counting).
The laboratory performs karyotyping on hematological malignancies along with Fluorescent in situ hybridisaiton (FISH). Solid tumors are studied by performing FISH analysis on formalin fixed paraffin embedded tissue sections as well as cell blocks and cytology smears. Along with stress cytogenetics the department has also used high density arrays to characterize copy number variations in acute leukaemias.
List of FISH Probes available
FISH (Fluorescence in situ hybridization) - Hematological Malignancies:
B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | |||
Hyper/Hypodiploidy | Ph Like ALL | B – Others | |
• ETV6/RUNX1 – t(12;21)
• BCR/ABL1- t(9;22) • KMT2A/MLL-11q23v • E2A • E2A/PBX1/HLF |
• CEP 4
• CEP 10 • CEN 17 • 7/15/17 |
• ABL1
• ABL2 • CRLF2 • CSF1R • EPOR1 • JAK2 • NTRK3 • PDGFRB |
• ETV6
• IgH • CDKN2A • cMYC • IgH/cMYC • ZNF384 • MEF2D/BCL9 • Sub telomeric 21 – iAMP21 |
T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | |||
• BCR/ABL1- t(9;22)
• ABL1 • KMT2A/MLL-11q23v • NUP98 |
MULTIPLE MYELOMA* | CHRONIC LYMPHOCYTIC LEUKEMIA | ||||
• TP53/CEN 17
• IgH • CDKN2C/CKS1B -1p32/1q21 • 5p15/9q22/15q22 *CD138 Enriched |
• IgH/FGFR3-t(4;14)
• IgH/CCND3-t(6;14) • IgH/cMYC –t(8;14) • IgH/CCND1-t(11;14) • IgH/MAF-t(14;16) • IgH/MAFB-t(14;20) |
• TP53
• ATM • CEP12 • RB1/13q |
|||
ACUTE MYELOID LEUKEMIA | |||||
• AML1/ETO t(8;21)
• CBFb – inv(16) or t(16;16) • PML/RARα t(15;17) • RARα • BCR/ABL1 – t(9;22) • KMT2A/MLL – 11q23 • KMT2A/MLLT3 – t(9;11) • NUP98 |
• GATA2-MECOM 3q
• Del 5q • CEP7/Del 7q • TP53/CEN 17 • 20q12 – PTPRT • CEP 8 |
||||
MYELODYSPLASTIC SYNDROME | MYELOPROLIFERATIVE NEOPLASM |
• GATA2-MECOM 3q
• Del 5q • CEP7/Del 7q • TP53/CEN 17 • 20q12 – PTPRT • KMT2A/MLL – 11q23 • CEP 8 |
• BCR/ABL1 – t(9;22)
• PDGFRA/FIP1L1/CHIC2 • PDGFRb • FGFR1 • JAK2 |
• CEP XX/XY in Opposite Sex Bone Marrow Transplant (BMT) |
FISH (Fluorescence in situ hybridization) - Solid Malignancies:
Ca Breast/Gastric | Ca Lung | CNS Tumour |
• CEN 17/ERBB2 | • ALK
• ROS1 • MET • RET |
• 1p/19q
• MYCN • cMYC/CEN8 • TP53/CEN 17 |
Lymphoma | Sarcoma | Renal Cell Ca | Mammary Analogue Ca | |
• cMYC
• BCL6 • BCL2 • IgH • cMYC-IGH • BCL2-IGH • CCND1/IGH • IRF4, DUSP22 |
• FOXO1
• MDM2/CEN 12 • RET • FUS • SS18/SYT • EWSR1 |
• TFE3
• NTRK3 |
• ETV6
• NTRK3 |
1. Karyotyping – 750
2. FISH
(a) Liquid/Hemat FISH – 1100
(b) Solid Tumour FISH – 1000
(c) Her2Neu – 3503Stress Cytogenetics/Fanconis – 20
3. Stress Cytogenetics/Fanconis – 20
4. Constitutional Karyotyping – 10
Total (including Karyotyping & FISH) – 3300 approximately annually.